Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Bayer | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Computed tomographic angiography (CTA) is an important prognostic tool with regard to the detection of coronary artery stenoses. Both iodine delivery rate (IDR; the amount of iodine delivered to the patient per second) and iodine concentration are decisive factors in the opacification of arterial vessels.
There remains to be some debate in the literature about whether the use of high iodine concentration contrast media is beneficial compared to lower iodine concentrations.
To date, there have not been any studies comparing intracoronary attenuation using concentrated contrast media lower than 300 mg I/ml at coronary CTA. For a reliable comparison of CM with different iodine concentrations, adapted injection protocols insuring an identical IDR (in g iodine per second) are mandatory. The investigators hypothesize that usage of lower iodine concentrations, while maintaining identical IDR and total iodine load, will result in comparable diagnostical intra-vascular attenuation in CTA.
To evaluate intravascular contrast enhancement and image quality in coronary CTA using different iodine concentrations ranging from 240 to 370 mg iodine per ml, administered with an identical IDR and total iodine load.
To describe the effect of iodine concentration and flow rates on contrast bolus characteristics, eg time to peak, bolus homogeneity, injection pressure and patient comfort.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 240 | Experimental | Group 240 will receive CM with 240 mg Iodine/ml IDR 2.0 gI/s |
|
| 300 | Experimental | Group 300 will receive CM with 300 mg Iodine/ml IDR 2.0 gI/s |
|
| 370 | Experimental | Group 370 will receive CM with 370 mg Iodine/ml IDR 2.0 gI/s |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 240 mg Iodine | Drug |
|
| |
| 300 mg Iodine |
| Measure | Description | Time Frame |
|---|---|---|
| intravascular contrast enhancement | intravascular contrast enhancement and image quality based on different contrast media (240, 300, 370) as measured by circular ROI in the target vessels using dedicated post processing. | two years |
| Measure | Description | Time Frame |
|---|---|---|
| time to peak | Effect of iodine concentration - as measured by dedicated contrast monitoring software. | two years |
| bolus homogeneity | Effect on contrast bolus characteristics and injection pressure - as measured by dedicated contrast monitoring software. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Maastricht University Medical Center | Maastricht | 6202AZ | Netherlands |
Not provided
| ID | Term |
|---|---|
| D003324 | Coronary Artery Disease |
| D023921 | Coronary Stenosis |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D007455 | Iodine |
| ID | Term |
|---|---|
| D006219 | Halogens |
| D004602 | Elements |
| D007287 | Inorganic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
|
| 370 mg Iodine | Drug |
|
|
| two years |
| patient comfort | Effect on patient comfort. As assessed by patient questionnaire. | two years |
| D001161 |
| Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |